Item 1A. Risk Factors
16K characters. Original on sec.gov ·
Item 1A. Risk Factors
Our business faces many risks and uncertainties that we cannot control. The risk factors described in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the below risk factors, should be carefully considered, together with the other information contained in this Quarterly Report on Form 10-Q and in our other filings with the SEC, in connection with evaluating the Company, our business, and the forward-looking statements contained in this Quarterly Report on Form 10-Q. Other risks that we do not presently know about or that we presently believe are not material could also adversely affect us. The risk factors described below update the risk factors disclosed in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, to include additional information.
We may encounter difficulties integrating our and Kenvue’s businesses and operations and, therefore, may fail to realize the projected benefits and cost savings of the Kenvue Acquisition, which could adversely affect the value of our common stock. The significant additional indebtedness that we incurred and our issuance of additional shares in connection with the Kenvue Acquisition could have negative consequences.
We are in the process of integrating a large number of manufacturing, operational and administrative systems to achieve consistency throughout the combined company, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes. This integration is a complex, costly and time-consuming process. If any difficulties in the integration of our operations were to occur, they could adversely affect our business, including, among other ways, causing a failure to meet demand for our products, or adversely affect our ability to meet our financial reporting obligations. Inconsistencies in standards, controls, procedures and policies may adversely affect our ability to maintain relationships with customers, suppliers, distributors, alliance partners, and creditors.
The success of the combined company will depend, in part, on our ability to realize the anticipated benefits and cost savings from combining K-C’s and Kenvue’s respective businesses, including operational and other synergies that we believe the combined company will be able to achieve. The anticipated benefits and cost savings of the Kenvue Acquisition may not be realized fully or at all, may take longer to realize than expected or could have other adverse effects that we do not currently foresee. If we are unable to successfully combine the businesses in an efficient, cost-effective manner within the anticipated timeframe, the projected benefits and cost savings may not be realized fully or may take longer to realize than expected and our business may be unable to grow as planned, which could materially impact our business, cash flow, financial condition or results of operations as well as adversely impact our share price.
We have incurred significant financial advisory, legal, accounting, consulting and other advisory fees, severance/retention employee benefit-related costs, regulatory fees and other costs relating to the Kenvue Acquisition. We expect to continue to incur substantial non-recurring costs in connection with integrating the operations of K-C and Kenvue, including costs to replace services and manufacturing that Kenvue currently receives from Johnson & Johnson ("J&J") under transitional arrangements.
The Kenvue Acquisition increased the amount of our debt resulting in additional interest expense. Furthermore, additional cash will be required for any dividends declared due to the additional shares issued in connection with the Kenvue Acquisition. Both of these factors could reduce our financial flexibility to continue capital investments, develop new products and declare future dividends.
Events outside our control, including changes in regulation and laws as well as economic trends, also could adversely affect our ability to realize the expected benefits from this acquisition.
Concerns about the reliability, safety, or efficacy of our products or their ingredients could result in litigation, regulatory action, reputational damage, product recalls, product reformulations, or product withdrawals, which could adversely affect us.
Concerns about the reliability, safety or efficacy of our products or their ingredients could result in governmental investigations, regulatory action (including the shutdown of manufacturing facilities), private claims and lawsuits, recalls, reformulations, significant remediation and related costs, safety alerts, marketing prohibitions, product shortages, declining sales or reputational damage. This is true whether the concerns are raised internally or by litigants, regulators, consumer advocacy groups or others, and whether or not they are based on sound scientific or factual evidence. These risks have increased as a result of the Kenvue Acquisition, which added a significant
portfolio of OTC medicines and skin health products to our business. Kenvue has in the past paid, and we may be required in the future to pay, for losses or injuries purportedly caused by its products. If a product or ingredient is perceived or found to be contaminated, tampered with, defective, ineffective, or unsafe, we may need to recall, reformulate or withdraw the product. Product liability insurance and other applicable insurance policies may not be available on acceptable terms or may not be sufficient to cover our losses.
Recalls, reformulations and withdrawals of various sizes have occurred across Kenvue’s business segments and may occur in the future. Scrutiny of the ingredients in our products, including scrutiny that starts on digital or social media platforms, may restrict or prevent our use of those ingredients or require remedial action. That could cause us to incur significant costs, particularly if we reformulate or withdraw the affected products, or could lead to litigation. For example, regulators including the Federal Drug Administration ("FDA") and the European Medicines Agency have issued guidance on assessing and controlling nitrosamine impurities in medicines, and we are reviewing Kenvue’s product portfolio under that guidance.
In addition, in September 2023, the FDA's Nonprescription Drugs Advisory Committee (the "NDAC") concluded that the scientific data did not support the effectiveness of orally administered phenylephrine ("PE") at the recommended dosage as a nasal decongestant. PE is an ingredient in certain Kenvue products, including Sudafed PE and Tylenol Cold & Flu. In November 2024, the FDA proposed removing oral PE from the applicable OTC monograph, which, if finalized, could require us to reformulate or remove affected products from the market. Following the NDAC’s determination, putative class actions were filed against Kenvue and its affiliates, asserting claims including violations of consumer protection statutes and federal securities laws, negligence, and unjust enrichment. These developments could result in substantial litigation costs or liabilities, reduced sales, or other adverse effects on our business.
Separately, claims for personal injury have been made against Kenvue Brands LLC (formerly known as Johnson & Johnson Consumer Inc.), now our subsidiary, along with other sellers of acetaminophen-containing products, alleging that in utero exposure to acetaminophen, the active ingredient in Tylenol®, is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder in children. Additional product liability lawsuits continue to be filed, and related matters include citizens' petitions and a lawsuit filed by the Attorney General of Texas. We continue to receive information with respect to potential costs and the anticipated number of cases. At this stage, we are unable to reasonably estimate the likelihood or magnitude of potential liability arising from these matters. Adverse outcomes, significant settlements or judgments, or the costs of defending these matters could be substantial. Moreover, governmental statements, labeling changes and adverse publicity relating to acetaminophen, whether or not supported by sound scientific evidence and whether or not directed at our products, may impact sales of Tylenol® and other acetaminophen-containing products, damage the reputation of our brands and increase the risk of future claims, any of which could adversely affect our business, results of operations, cash flows or financial condition.
These are not the only such matters, and future matters may be of similar, greater, or lesser significance.
Kenvue’s historical relationship with J&J exposes us to increased risks, including in relation to reliance on J&J under transitional agreements, indemnification obligations to J&J and the possibility that J&J’s indemnities to us, including for talc-related liabilities, will not be sufficient.
Kenvue was separated from J&J in 2023 and continues to depend on J&J for certain manufacturing and other services. Under a transition manufacturing agreement, J&J supplies specified products or components, including Motrin®, Tylenol® and Zyrtec®. Any failure or delay by J&J in performing these services could impair our ability to deliver quality products in necessary quantities, damage our brands and increase our costs. As these agreements expire, we must transition the relevant manufacturing and services to our own operations or to third parties, which is complex, time-consuming and costly and could increase the risk of manufacturing defects or quality control issues. In addition, pursuant to the separation agreement, certain assets and liabilities, including of Kenvue’s operations in China, and certain contracts, permits and licenses have not yet been transferred from J&J in order to ensure compliance with applicable law, to obtain necessary governmental approvals and other consents, and for other business reasons, and such transfers may be significantly delayed or may not occur. Prior to such transfer, the net profits or losses from the operation of such business will, to the extent reasonably practicable and permitted by applicable law, be provided to us.
The separation agreement and other agreements between Kenvue and J&J provide for indemnification obligations for uncapped amounts (reduced by any insurance proceeds or other third-party proceeds that the party being indemnified receives), designed to make Kenvue financially responsible for substantially all liabilities relating to its business activities, whether incurred before or after the separation. As one example, J&J has received demands for
indemnification for legal claims related to OTC Zantac (ranitidine) products sold by third parties in the United States, and Kenvue has agreed to indemnify J&J for such claims. Kenvue also has obligations to indemnify J&J and certain underwriting banks in pending securities litigation about disclosures relating to oral PE made in connection with Kenvue's 2023 IPO and J&J's subsequent exchange offer. Conversely, J&J has retained, and agreed to indemnify Kenvue for certain liabilities, including relating to talc and talc-containing products sold in the United States and Canada. However, third parties have sought, and may continue to seek, to hold our subsidiaries responsible for liabilities J&J has retained, J&J’s indemnity may not be sufficient to cover the full amount of such liabilities, J&J’s ability to satisfy its indemnification obligations could be impaired, and J&J’s insurance policies may not be available to us. In addition, pursuant to Kenvue’s separation agreement with J&J, J&J’s self-funded insurance policies are not available to us, and J&J’s third-party insurance policies may not be available to us, for liabilities associated with occurrences of indemnified liabilities prior to Kenvue’s separation from J&J, and in any event J&J’s insurers may deny coverage to us for liabilities associated with certain occurrences of indemnified liabilities prior to the separation. Furthermore, even where we are ultimately entitled to indemnification, we may be required to bear losses temporarily. In addition, J&J’s indemnity does not cover talc-related liabilities arising from products sold outside the United States and Canada, which remain our responsibility. Kenvue is currently subject to talc-related claims outside the United States and Canada, including in the United Kingdom, and we cannot reasonably estimate the likelihood or magnitude of potential liability arising from these claims. Any of these matters could adversely affect our business, results of operations, cash flows or financial condition.
As a result of the Kenvue Acquisition, we are now subject to additional risks relating to the production and sale of OTC drug and other healthcare products.
Following the Kenvue Acquisition, a significant portion of our business consists of OTC medicines and other healthcare products, which are subject to extensive regulation by the FDA, the U.S. Federal Trade Commission, the U.S. Drug Enforcement Administration and other federal, state and foreign authorities. We and our third-party manufacturers must register facilities with these authorities and manufacture products in accordance with current Good Manufacturing Practice ("cGMP") requirements. Compliance with these requirements necessitates substantial expenditures across training, recordkeeping, production, quality control and quality assurance. A failure to comply with cGMP or other requirements at our facilities or those of our third-party partners could result in warning letters, product recalls or seizures, facility shutdowns, fines, injunctions or other regulatory action. We have not historically operated an OTC drug business of this scale, and we must integrate Kenvue’s quality and regulatory systems into our broader operations. In addition, new or more stringent laws or regulations, more restrictive interpretations of existing laws or regulations, or increased enforcement actions could increase our ongoing costs of global compliance, alter the environments in which we do business, or otherwise adversely affect our business, results of operations, or financial condition. A finding that we are in violation of, or out of compliance with, applicable laws or regulations could subject us to civil remedies, including fines, damages, injunctions, or product recalls, or criminal sanctions, any of which could adversely affect our business, results of operations, or financial condition.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. On January 22, 2021, our Board of Directors authorized a share repurchase program that allows for the repurchase of 40 million shares in an amount not to exceed $5 billion. As of September 30, 2026, the Company has repurchased approximately 9.2 million shares and approximately 30.8 million shares remain available for repurchase under the program. No shares were repurchased during the three months ended September 30, 2026.
Previous: Item 4. Controls and Procedures · Next: Item 5. Other Information